Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted ...

According to experts, prenatal nutrition is paramount to the health of both mother and baby, with several nutrients being critical(1). In fact, the USDA Dietary Guidelines 2020-2025 recommends that ...

Issei, the world’s first mochi gummy brand, welcomes engineer and entrepreneur Yamrot Ezineh as a Strategic Advisor. With extensive experience in process ...

"Whether bringing new therapies to market or managing teams, the pursuit of excellence drives meaningful impact." ...

One of the palaces the Boutique Group has been working on, for example, is the Red Palace, which the company touts as the first building in Riyadh city (the capital of Saudi Arabia) to be constructed ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

AstraZeneca recently reported a 1.9% decline in its share price over the last week. This movement coincides with the broader market's downturn, which saw a 1.1% drop amid ongoing concerns about ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

AstraZeneca has rejoined PhRMA as it expands its “presence in the United States with significant investments in research, development and manufacturing,” Pascal Soriot, AZ’s CEO, said in a ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

The CEO of FTSE 100 giant Astrazeneca has spoken out. (Photo by Christopher Furlong/Getty Images) Europe is putting its “ability to protect the health of its own people at risk” by not ...

April 22 (Reuters) - AstraZeneca (AZN.L), opens new tab has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers of America ...